B+
Bull case
25%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
BCAX
Bicara TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
On-time pivotal enrollment, constructive colorectal data and eventual randomized confirmation could broaden the value attributed to ficerafusp alfa. Bicara reported $497.3 million of cash, equivalents and marketable securities at June 30 and projected funding into the first half of 2029 [#IR-2026-08-11] ([company release](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2026-progress-and)).
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -17.1.
What can break
Binary clinical and regulatory risk remains concentrated in ficerafusp alfa and the FORTIFI-HN01 pivotal program.
Momentum
14
Value
41
Sentiment
79
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $22.00 · Bull $34.00 · Bear $10.00Analysis 2026-09-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-09-24 • Vendor: Data Vendor v1
Scores
As of 2026-09-25 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-25
Investment thesis
As of 2026-09-25
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-25. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $33.92
Why
Momentum14 · Δ7d -8.6
Value41 · Δ7d -0.1
Sentiment79 · Δ7d -17.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -17.1.
Contradictions & invalidation
- • Binary clinical and regulatory risk remains concentrated in ficerafusp alfa and the FORTIFI-HN01 pivotal program.
- • Form 4 records show executive open-market sales in August and September, but those transactions do not establish operating weakness [#SEC-FORM4-2026-08-12] [#SEC-FORM4-2026-09-10].
- • The thesis is concentrated in one lead asset.
Catalyst clock
2026-12-31
Metastatic colorectal cancer cohort data
Lead driver: Sentiment · See AI snapshot
Momentum
14
9% active weight
Current posture
7d trendFlat
Δ7d
-8.6
Δ21d
-1.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
79
62% active weight
Current posture
7d trendSoftening
Δ7d
-17.1
Δ21d
-16.4
Why this grade
Composite grade B. Momentum 13.6 / Value 41.1 / Sentiment 78.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-09-24
Fundamentals (TTM)
As of 2026-09-24
Market Cap
$1.31B
Beta
-
Shares Out
66.17M
P/E (TTM) · Derived
-7.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.81
Rev YoY
-
EPS YoY
+62.5%
Gross Margin
-
Op Margin
-
Net Debt
-$413.09M
Current Ratio
11.59
As of 2026-09-25 • Updated nightlySource: Internal modelMethods & Data